



# The ACME Laboratories Ltd.

MANUFACTURERS OF ETHICAL DRUGS & MEDICINES

ISO 9001:2008 CERTIFIED COMPANY

Ref. No. ACME /CA/CS/0130/2019

10 October 2019

**The Chairman**

Bangladesh Securities and Exchange Commission  
Securities Commission Bhaban  
E-C/6, Agargaon,  
Sher-e-Bangla Nagar Administrative Area,  
Dhaka-1207.

**Subject: Audited Status Report on utilization of Initial Public Offering proceeds of The ACME Laboratories Ltd.**

Dear Sir,

In compliance with the clause 3 & 4 of Part-C of the Letter of Consent vide no. BSEC/CI/BB-03/2014/143; dated: 15 March 2016 accorded by your esteemed organization, we are pleased to enclose herewith the Audited Status Report (as per revised format) on utilization of Initial Public Offering proceeds of The ACME Laboratories Ltd. duly authenticated by the Board of Directors in its 108<sup>th</sup> Meeting held on 09 October 2019 for your kind perusal and record please.

Thanking you and assuring of our best attention for all the time to come.

  
**Mizanur Rahman Sinha**  
Managing Director

**Enclosure:** As stated above



Copy to:

01. The Managing Director, Dhaka Stock Exchange Limited
02. The Managing Director, Chittagong Stock Exchange Limited
03. The Chief Executive Officer, ICB Capital Management Limited

**Corporate Office:**

**Court de la ACME**

1/4, Kallayanpur, Mirpur Road  
Dhaka-1207, Bangladesh.  
Phone: +88-02-9004194-6  
Fax: +88-02-9016872  
E-mail: headoffice@acmeglobal.com

[www.acmeglobal.com](http://www.acmeglobal.com)

**Plant:**

Dhamrai, Dhaka, Bangladesh  
Phone: +88-02-7730881-2  
88-02-7730816-7, 7730142  
Fax: +88-02-7730141  
E-mail: plant@acmeglobal.com

# Auditors' Report



Name of Client

**The ACME Laboratories Ltd.**  
**Utilization of IPO Proceeds**  
for the month ended 30 September 2019

**পিনাকী এণ্ড কোম্পানী**  
**Pinaki & Company**

REGD. OFF : AHSANDELL, 2/A, Mymensingh Road (2nd Floor), Shahbag, Dhaka-1000, Bangladesh  
Tel # 966-0944, 966-5095, Cell: 01317-201224, 01711-106302  
E-mail : pinaki\_co@yahoo.com, website: www.pinaki.com.bd



**AUDITORS' REPORT**  
*on*  
**Utilization of IPO Proceeds**

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of The ACME Laboratories Ltd. for the month ended 30 September 2019.

**Management's Responsibility for the IPO proceeds Utilization**

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

**Auditor's Responsibility**

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA), Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

**Opinion**

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, Prepared in accordance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 gives a true and fair view of the statement for the month ended 30 September 2019 and comply with the resolution of 42<sup>nd</sup> AGM of the company.

**As per TOR, We draw attention to the following matter:**

1. The Company has started commercial operation of Steroid and Hormone project in the month of June 2019, which has been completed within the time limit approved by the shareholders in its 42<sup>nd</sup> AGM. Total project cost of BDT 1,660,591,186 is generated from the IPO fund.





2. The Company has started commercial operation of Penicillin project in the month of June 2019, which has been completed within the time limit approved by the shareholders in its 42<sup>nd</sup> AGM. Total project cost of BDT 400,000,000 is generated from the IPO fund.
3. The Company has also utilized accumulative amount of Tk.177,888,594 up to 31 August 2019 in respect of API Project. During the month of September 2019, no amount has been utilized out of IPO fund in respect of Active Pharmaceuticals Ingredients (API) Project.

**We also state that:**

- a) IPO proceeds have been utilized for the purposes as specified in the resolution of 42<sup>nd</sup> AGM of the company;
- b) IPO proceeds have been utilized in line with the conditions of the BSEC's consent letter for the IPO;
- c) API project, for which IPO fund was raised, will be completed within the time frame as specified in the resolution of 42<sup>nd</sup> AGM of the company.
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the resolution of 42<sup>nd</sup> AGM of the company;
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

Date: 10 October 2019  
Dhaka.

**Pinaki & Company**  
Chartered Accountants

Report on Utilization of IPO Proceeds  
For the Month of September 2019

Name of the Company: The ACME Laboratories Ltd.  
Amount (BOT) of capital raised through IPO: BDT 4,096,000,000 (Received amount BDT 4,095,015,601, 38 net of foreign currency conversion loss)  
Date of Close of Subscription: 21 April 2016  
Proceeds Receiving Date: 11 April 2016 to 21 April 2016  
Last Date of full Utilization of IPO fund as per 40th AGM/42nd AGM: As stated in time line columns

S.I	Purpose mentioned in the 40th AGM/42nd AGM	Time Line	As per 40th AGM	As per 42nd AGM	Cost Breakdown	Amount as per 40th AGM	Amount as per 42nd AGM	Opening	During the Month	Status of Utilization		Total un utilized amount	Un utilized %	Remarks
										Total Utilized Amount	Utilized %			
1	Steroid and Hormone Project	Within 2 years of receiving IPO fund, i.e. 2018		Within June 2019	Civil Construction	335,800,000	334,934,878	334,934,878	-	334,934,878	100.00%	-	0.00%	Rearrangement of Utilization Plan has been approved in 42nd AGM as on 6 December 2018 and IPO Utilization Proceeds certified by M/s. Pinaki and Company, Chartered Accountants
					Machinery & Equipment	598,600,000	933,900,000	933,900,000	-	933,900,000	100.00%	-	0.00%	
					Utility	339,600,000	353,700,000	353,700,000	-	353,700,000	100.00%	-	0.00%	
					Warehouse	39,500,000	21,986,000	21,986,000	-	21,986,000	100.00%	-	0.00%	
					Vehicle	5,000,000	5,000,000	5,000,000	-	5,000,000	100.00%	-	0.00%	
2	Penicillin Project	Within the month of March 2018		Within June 2019	Consultancy fee	26,300,000	1,200,000	1,200,000	-	1,200,000	100.00%	-	0.00%	Rearrangement of Utilization Plan has been approved in 42nd AGM as on 6 December 2018 and IPO Utilization Proceeds certified by M/s. Pinaki and Company, Chartered Accountants
					Contingencies	13,200,000	9,870,308	9,870,308	-	9,870,308	100.00%	-	0.00%	
					Sub Total	1,358,000,000	1,660,591,186	1,660,591,186	-	1,660,591,186	100.00%	-	0.00%	
					Civil Construction	116,000,000	142,922,303	142,922,303	-	142,922,303	100.00%	-	0.00%	
					Machinery & Equipment	132,299,520	79,768,602	79,768,602	-	79,768,602	100.00%	-	0.00%	
3	Active Pharmaceuticals Ingredients (API)	Within 2-3 years after getting permission from the Ministry of Industries		Within June 2022	Utility	117,154,000	146,345,797	146,345,797	-	146,345,797	100.00%	-	0.00%	Rearrangement of Utilization Plan has been approved in 42nd AGM as on 6 December 2018 and IPO Utilization Proceeds certified by M/s. Pinaki and Company, Chartered Accountants
					Warehouse	20,582,700	21,641,545	21,641,545	-	21,641,545	100.00%	-	0.00%	
					Vehicle	3,000,000	2,901,503	2,901,503	-	2,901,503	100.00%	-	0.00%	
					Consultancy fee	5,963,780	1,420,250	1,420,250	-	1,420,250	100.00%	-	0.00%	
					Contingencies	5,000,000	5,000,000	5,000,000	-	5,000,000	100.00%	-	0.00%	
4	Repayment of Bank Borrowing at 42th AGM	N/A		N/A	Sub Total	400,000,000	400,000,000	400,000,000	-	400,000,000	100.00%	-	0.00%	Rearrangement of Utilization Plan has been approved in 42nd AGM as on 6 December 2018 and IPO Utilization Proceeds certified by M/s. Pinaki and Company, Chartered Accountants
					Civil Construction	347,860,000	355,637,304	177,888,594	-	177,888,594	50.02%	177,748,710	49.98%	
					Machinery & Equipment	493,000,000	250,495,241	-	-	-	0.00%	250,495,241	100.00%	
					Utility	409,400,000	-	-	-	-	-	-	-	
					Warehouse	38,500,000	-	-	-	-	-	-	-	
5	IPO Expenses	N/A		N/A	Vehicle	3,000,000	-	-	-	-	-	-	-	Rearrangement of Utilization Plan has been approved in 42nd AGM as on 6 December 2018 and IPO Utilization Proceeds certified by M/s. Pinaki and Company, Chartered Accountants
					Consultancy fee	23,635,200	-	-	-	-	-	-	-	
					Contingencies	12,917,600	-	-	-	-	-	-	-	
					Initial Working Capital	26,915,492	-	-	-	-	-	-	-	
					Sub Total	1,355,228,292	606,132,545	177,888,594	-	177,888,594	29.35%	428,243,951	70.65%	
Total						1,350,000,000	1,360,000,000	1,360,000,000	-	1,360,000,000	100.00%	-	0.00%	Rearrangement of Utilization Plan has been approved in 42nd AGM as on 6 December 2018 and IPO Utilization Proceeds certified by M/s. Pinaki and Company, Chartered Accountants
						68,291,870	68,291,870	68,291,870	-	68,291,870	100.00%	-	0.00%	
						4,541,520,162	4,095,015,601	3,666,771,650	-	3,666,771,650	89.54%	428,243,951	10.46%	

Percentage (Interest on FDR to be matured on 08 October 2019 & 27 December 2019)

Interest on IPO Proceeds in BOT (from FDR & SND)

Un-Utilized IPO Proceeds with Interest Income in BOT

On Behalf of Board

*(Signature)*  
Fazla Haque, FCA  
Independent Director & Chairman of Audit Committee

*(Signature)*  
Mizanur Rahman Sinha  
Managing Director

*(Signature)*  
Nagina Afzal Sinha  
Chairman

*(Signature)*  
Pinaki & Company  
Chartered Accountants